Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
The Lancet. Oncology.
Times cited: 10
- The Translational Research Working Group developmental pathways: introduction and overview. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
- Workshop on imaging science development for cancer prevention and preemption. Cancer biomarkers : section A of Disease markers. 2007 Conference Paper GET IT
- COX-2 in cancer - A player that's defining the rules. Journal of the National Cancer Institute. 2002 Editorial Article GET IT